Use este identificador para citar o ir al link de este elemento:
http://hdl.handle.net/1843/63456| Tipo: | Artigo de Periódico |
| Título: | Therapeutic uses for Angiotensin-(1-7) |
| Autor(es): | Alice Machado-Silva Danielle Passos-Silva Robson Augusto Souza dos Santos Rubén Dario Sinisterra Millán |
| Resumen: | Introduction: Angiotensin-(1-7) is a key component of the Renin-Angiotensin System, which can counter-regulate several deleterious effects caused by angiotensin II. Due to the potential for therapeutic use, several of its actions are specifically described in patents. Areas covered: In this review, the authors describe a plethora of therapeutic uses for Angiotensin-(1-7), claimed and supported by experimental evidence in patent documents and applications. Expert opinion: The clinical potential of Angiotensin-(1-7) as a therapeutic agent to treat several pathologies is evidenced by the variety of patents and clinical trials involving this peptide. Cancer treatment is one of the most advanced therapeutic areas, but clinical studies are also available in several other areas, such as cardiovascular, hematological, transplantation, surgical and medical procedures. |
| Asunto: | Angiotensina - Uso terapêutico Sistema renina-angiotensina Patentes Câncer - Tratamento |
| Idioma: | eng |
| País: | Brasil |
| Editor: | Universidade Federal de Minas Gerais |
| Sigla da Institución: | UFMG |
| Departamento: | ICB - DEPARTAMENTO DE FISIOLOGIA E BIOFÍSICA ICX - DEPARTAMENTO DE QUÍMICA |
| Tipo de acceso: | Acesso Restrito |
| Identificador DOI: | https://doi.org/10.1080/13543776.2016.1179283 |
| URI: | http://hdl.handle.net/1843/63456 |
| Fecha del documento: | 2016 |
| metadata.dc.url.externa: | https://www.tandfonline.com/doi/full/10.1080/13543776.2016.1179283 |
| metadata.dc.relation.ispartof: | Expert Opinion on Therapeutic Patents |
| Aparece en las colecciones: | Artigo de Periódico |
archivos asociados a este elemento:
no existem archivos asociados a este elemento.
Los elementos en el repositorio están protegidos por copyright, con todos los derechos reservados, salvo cuando es indicado lo contrario.